MISSISSAUGA, ON, March 9,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical
technologies company, today is delighted to announce that
Martin Goldfarb has joined its Board
of Directors.
Brian Pedlar, Covalon's CEO,
said, "I am very pleased to welcome Martin
Goldfarb back on Covalon's Board. Martin has been a
significant, longstanding shareholder of Covalon, and I look
forward to once again benefiting further from his unique insights
and experiences."
Martin Goldfarb said, "I have
been an enthusiastic investor in Covalon for over a decade. I love
that Covalon successfully innovates in the healthcare arena –
saving lives by developing new medical technologies. I look forward
to contributing to Covalon's further progress. I sincerely believe
there is much more that can be achieved by Covalon for patients,
healthcare providers, and shareholders alike."
Mr. Goldfarb is well-recognized as a successful entrepreneur and
a leading expert in the study of human behavior as it relates to
the marketplace and society. As an officer, director, and investor
in both public and private companies, Mr. Goldfarb has been
instrumental in brand and strategic development, management
mentoring, and the creation of value, ultimately leading to
substantial return on investment.
Mr. Goldfarb is Chairman of Almada Inc., President of Goldfarb
Ventures, private equity companies, and Principal at Goldfarb
Intelligence Marketing.
In 1966, Mr. Goldfarb established Goldfarb Consultants, a market
research consulting firm. Over the next thirty years, he proceeded
to grow the company and to establish Goldfarb Consultants as a
leader in the field of market research. Starting in Toronto, he built Goldfarb Consultants into an
international company with 26 worldwide offices. Mr. Goldfarb sold
Goldfarb Consultants in 1998.
Mr. Goldfarb has consulted to a number of national and
international organizations. He also served as official pollster to
the Liberal Party of Canada from
1973 to 1992. He was formerly Co-Chair of Kantar (WPP's market
research division).
Mr. Goldfarb is Chairman, President and CEO of The Goldfarb
Corporation, a TSX and then a NEX Board of the TSX Venture Exchange
company, until it became a private corporation in 2011. He is a
director of NoNO Inc., a pharmaceutical research company.
He was also Director and Chairman of Dayforce, a workforce
performance software company until its sale. He was Chairman and
Director of SMK Speedy International Inc (publicly listed) until
its sale in 2004. Under Mr. Goldfarb's guidance, Speedy Muffler
King became a strong and successful brand in France, Belgium and Germany. He was Director, investor, and
non-executive Chair of Jempak until its sale. Mr. Goldfarb is
former Director and Chairman of Workbrain and former Director of
Altamira and Noma Industries Limited. He was a founder of Fast
Company magazine.
Mr. Goldfarb co-authored "Marching to a Different Drummer" in
1988 and "Affinity: Beyond Branding" in 2010.
Mr. Goldfarb has a B.A. in Anthropology and an M.A. in Sociology
from the University of Toronto. In
2009, Mr. Goldfarb was awarded an Honorary Doctorate of Laws from
York University. He is an inaugural
recipient of the University College, University of Toronto, Distinguished Alumni
Award.
In 1998, Mr. Goldfarb was designated an Officer of the Order of
Canada in recognition of his
pioneering work in the market research industry and philanthropic
activities.
Mr. Goldfarb sits on the Toronto
General and Western Hospital Foundation board and is a member of
the hospital's Peter Munk Cardiac Centre Innovation Committee.
Mr. Goldfarb's appointment to Covalon's Board of Directors is
subject to TSX approval.
For those interested in learning more about Covalon's solutions,
visit www.covalon.com or follow Covalon on LinkedIn, Facebook,
Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results "may",
"could", "would", "might", "will" or "will be taken", "occur", or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which
is available on the Company's profile at www.sedar.com, any of
which could cause results, performance, or achievements to differ
materially from the results discussed or implied in the
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The forward-looking
statements contained in this news release are made as of the date
of this news release, and the Company assumes no obligation to
update or alter any forward-looking statements, whether as a result
of new information, further events, or otherwise, except as
required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-welcomes-martin-goldfarb-oc-to-its-board-of-directors-301767786.html
SOURCE Covalon Technologies Ltd.